What is the current stock price of IMV Inc. (IMVIQ)?

As of the latest market data, IMV Inc. (IMVIQ) is trading at $0.00. The stock has seen a loss of -90.00% today.

Does IMV Inc. (IMVIQ) pay a dividend?

Based on current data, IMV Inc. does not have a confirmed active dividend policy.

What is the market cap of IMV Inc.?

The current market capitalization of IMV Inc. (IMVIQ) is approximately unavailable.

IMVIQ

IMV Inc.·Healthcare

0.00

90.000%(−0.00)

Market Closed

Last Updated: — ET

52W L: $0.0052W H: $1.00

IMVIQ NEWS

defenseworld.net

Feb 26

Whitehawk Therapeutics (NASDAQ:WHWK) versus IMV (OTCMKTS:IMVIQ) Financial Review

IMV (OTCMKTS:IMVIQ - Get Free Report) and Whitehawk Therapeutics (NASDAQ: WHWK - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, analyst recommendations, dividends and profitability. Valuation and Earnings This table compares IMV and

Company Profile

IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and MSI-H solid tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2009-10-09

Beta

1.19

Websitewww.imv-inc.com↗